Table 2

Characteristics of patients from T cell-inflamed, intermediate, and non-T cell-inflamed tumor groups in the validate cohort (GMKF)

CharacteristicT cell-inflamed
N=89, no (%)
Intermediate
N=54, no (%)
Non-T cell-inflamed
N=55, no (%)
P-value
Age0.003**
 <18 months44 (49)39 (72)40 (74)
 ≥18 months45 (51)15 (28)14 (26)
 Unknown001
Sex0.5
 Female50 (56)28 (52)25 (45)
 Male39 (44)26 (48)30 (55)
Race0.9
 American Indian or Alaskan Native1 (1)0 (0)0 (0)
 Asian2 (2)2 (4)3 (6)
 Black or African American4 (5)4 (8)3 (6)
 White78 (92)43 (88)47 (88)
 Unknown452
Ethnicity0.2
 Hispanic or Latino2 (2)5 (10)3 (6)
 Not Hispanic or Latino84 (98)47 (90)50 (94)
 Unknown322
INSS stageNE
 Stage 127 (30)19 (35)12 (22)
 Stage 2A6 (7)3 (5)1 (2)
 Stage 2B14 (16)9 (17)7 (13)
 Stage 317 (19)7 (13)6 (11)
 Stage 424 (27)10 (19)19 (34)
 Stage 4S1 (1)6 (11)10 (18)
MYCN status<0.001***
 Amplified4 (4)2 (4)14 (26)
 Not amplified85 (96)52 (96)40 (74)
 Unknown001
Histology0.084
 Favorable55 (64)40 (77)30 (57)
 Unfavorable31 (36)12 (23)23 (43)
 Unknown322
Ploidy0.053
 Diploid/Hypodiploid25 (28)6 (11)13 (24)
 Hyperdiploid63 (72)48 (89)41 (76)
 Unknown101
COG risk group0.064
 High risk23 (26)7 (13)18 (33)
 Intermediate risk21 (24)11 (20)15 (27)
 Low risk45 (50)36 (67)22 (40)
  • P values were calculated using one-way analysis of variance, χ2 test, Fisher’s exact test.

  • *p<0.05, **p<0.01, ***p<0.001.

  • COG, Children’s Oncology Group; GMKF, Gabriella Miller Kids First; INSS, International Neuroblastoma Staging System; NE, Not Evaluable.